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Summary: 
Background: The recommended 6-month regimens for the treatment of pulmonary tuberculosis are highly effective in 
the setting of clinical trials, yet cumbersome to implement under practical conditions. Shorter treatment regimens would 
ease drug administration for both patients and providers: an effective. regimen of 3 or 4 months’ duration would have 
significant practical advantages for tuberculosis control. 
Methods: The study subjects were HIV negative adults with newly diagnosed. sputum smear and culture positive pulmonary 
tuberculosis. Eligible patients were randomly allocated to one of four regimens: (a) Ofloxacin. Isoniazid. Rifampicin. and 
Pyrazinamide daily for 3 months; (b) regimen(a). followed by Isoniazid and Rifampicin twice a week for 1 month: (c) 
regimen(a). followed by Isoniazid and Rifampicin twice a week for 2 months: or (d) Ofloxacin. Isoniazid. Rifampicin, and 
Pyrazinamide daily for 2 months, followed by Isoniazid and Rifampicin twice a week for 2 months. Each dose was 
administered under direct observation. The patients were assessed clinically and bacteriologically every month during and 
after treatment. Follow up will continue for 5 years; the results up to 24 months after treatment are presented here. 
Results :A total of 529 patients were admitted to the study. Data for efficacy analysis are available for 416 patients: 113 
were excluded primarily because of limited compliance. At the end of treatment, only 4 (1%) of 360 patients with initially 
drug-susceptible tuberculosis had an unfavourable bacteriological response (> 1 positive culture in the last 2 months of 
treatment). one patient in each regimen. Over a follow-up period of 2 years, 7 (8%) of 83, 3 (4%) of 81. 2 (2%) of 86. 
and 12 (13%) of 91 patients relapsed in regimens (a) through (d), respectively. Most (79%) of the relapses occurred in the 
6 months following the cessation of treatment. Of the 47 patients with tuberculosis initially resistant only to Isoniazid. 
2 (4%) had an unfavourable bacteriological response at the end of treatment. However, bacteriological relapse occurred in 
8 (19%) of 43 such patients who were assessed for relapse. Intention to treat analysis i.e. after including those who had 
inadequate therapy. of 469 patients (which had 53 patients who received inadequate chemotherapy). showed that only 4 
(3%) of 120. 6 (5%) of 115, 5 (4%) of 118 and 3 (3%) of I16 patients in the 4 regimens had an unfavourable 
bacteriological response at the end of treatment. Adverse reactions attributable to the anti-tuberculosis medications were 
observed in 3 1% (regimen d) to 44% (regimen c) of the patients. but a majority of the reactions were mild and manageable 
with symptomatic measures. Only 5% of patients had a reaction that required modification of the regimen. 
Corrclusions: Regimens of 4 or 5 months’ duration that contain Ofloxacin and other first-line anti-tuberculosis agents for 
at least three months can achieve high cure rates and low 24-month relapse rates in newly diagnosed patients with smear 
positive pulmonary tuberculosis without causing significant adverse reactions. These results indicate that Ofloxacin 
containing regimens of 4-5 months achieve >95% efficacy with no increased incidence of adverse reactions and minimal 
relapses. permitting shortening of short-course chemotherapy. 
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Clinical trials 
INTRODUCTION regimens are highly effective in the clinical trial 
setting, yet are cumbersome to implement under 
One of the long-term goals in tuberculosis control programme conditions. Shorter duration 
control has been to shorten the period of treatment treatment regimens would facilitate drug 
while maintaining high rates of cure with low rates administration, for both patients and treatment 
of relapse. The current, widely used 6-month providers; an effective, fully oral regimen of 3 or 4 
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months' duration would have significant practical 
advantages for patients as well as tuberculosis control 
programmes. In a previous randomized clinical trial, 
a 3-month regimen of daily Streptomycin, Isoniazid, 
Rifampicin, and Pyrazinamide resulted in a nearly 
100% favourable outcome at the end of treatment 
(all sputum cultures negative); yet 20% of the patients 
relapsed in the subsequent 21 months.1 Based on 
that experience, as well as the results of in vitro 
studies demonstrating the bactericidal activity of 
Ofloxacin2, we conducted a randomized, controlled 
clinical trial to assess the efficacy of regimens using 
Ofloxacin in the intensive phase for the treatment of 
smear-positive pulmonary tuberculosis. 
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OBJECTIVES 
To study the efficacy of 3-, 4-, and 5-month 
regimens using Ofloxacin in the intensive phase for 
the treatment of smear positive pulmonary 
tuberculosis, in terms of the proportions of patients 
who become culture negative at the end oftreatment 
and the proportion of patients who relapse during 
follow-up after treatment. The month by month 
sputum culture conversion and the occurrence of 
adverse reactions to the drugs used in the regimens 
were also studied. 
METHODS 
Patients : 
The study was conducted at our centres in 
two cities in south India. Chennai and Madurai. Study 
subjects were adult patients, at least 20 years old 
who had newly diagnosed smear positive pulmonary 
tuberculosis and lived within a designated area of 
our centres. For admission to the study, the patients 
were required to consent to undergo all the 
supervised outpatient treatment and allow home 
visits by centre staff. Those with previous treatment 
for tuberculosis exceeding 15 days were not eligible, 
nor were those with concomitant hypertension, 
diabetes mellitus, epilepsy, or serious forms of extra- 
pulmonary tuberculosis. Patients with fewer than two 
investigations, attend the health centre daily for 
positive sputum cultures initially, and those who were 
HIV sero-positive were excluded. lnformed consent 
was obtained from all the patients. 
Regimens and randomisation: 
Eligible patients who had at least two sputum 
smears positive for acid-fast bacilli were randomly 
allocated to one of the following four regimens, 
stratified on the degree of sputum smear grading of 
the penultimate home sputum specimen (first 
stratum- 0 or 1+ ; second stratum - 2+ or 3+ ): 
a. ( O3 ) - Ofloxacin, Isoniazid, Rifampicin, and 
Pyrazinamide daily for 3 months 
b. ( O3-1 ) - Regimen a, followed by Isoniazid and 
Rifampicin twice a week for 1 month 
c. ( O3-2 ) - Regimen a, followed by Isoniazid and 
Rifampicin twice a week for 2 months 
d. ( O2-2 ) - Ofloxacin, Isoniazid, Rifampicin, and 
Pyrazinamide daily for 2 months, followed 
by Isoniazid and Rifampicin twice a week 
Figure 1 : Treatment regimens 
Restricted random allocation sequences were 
generated by a statistician using random number 
tables, separately for the two strata and sealed 
envelopes were used to assign the regimens. Patients 
were enrolled in the study by the physicians, and 
when ready for allocation, the case sheet was sent 
to the statistician who drew the regimen from sealed 
envelopes depending on the stratum to which the 
patient belonged. 
The medication dosages were: Ofloxacin 
400 or 600 mg, Rifampicin 450 or 600 mg, and 
Pyrazinamide 1.5 or 2 g, depending on body weight 
(<40 kg or >40 kg); and Isoniazid 300 mg (daily 
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treatment) or 600 mg (twice-weekly treatment), 
irrespective of body weight. All drugs were 
administered under supervision as a single dose. 
Patients who missed clinic visits were visited at home 
and strongly encouraged to attend the clinic for 
treatment. 
Pre-treatment screening included four 
sputum specimens (two spot specimens and two 
overnight collections), which were examined by 
fluorescence microscopy3 and cultured for 
mycobacteria by the modified Petroffs method.4 
Positive cultures were idendified as Mycobacterium 
tuberculosis by standard methods.5,6 Drug 
susceptibility tests were performed on Lowenstein 
Jensen medium using a 4 mg/ml bacterial suspension 
by the resistance ratio method (Streptomycin) or the 
minimum inhibitory concentration method (Isoniazid, 
Rifampicin and Ofloxacin).7-10 The definitions of 
drug resistance for Rifampicin, Streptomycin and 
isoniazid were the same as used in previous studies1, 11; 
for Ofloxacin. drug resistance was defined as growth 
on 4 mg/l of the medium.10 The following 
investigations were also done: posterior-anterior 
chest radiograph; urine examination for albumin, 
glucose. bile pigments, acetyl Isoniazid, and 
Rifampicin; total and differential leucocyte counts, 
haemoglobin estimation. total erythrocyte and platelet 
counts: liver function (bilirubin. alanine transaminase, 
aspartate transaminase, alkaline phosphatase); renal 
function (serum urea and creatinine); serum uric acid; 
random blood glucose; and ELISA for HIV antibody. 
A physician examined the patient every 
month and recorded adherence to treatment. any 
adverse drug reactions and the clinical response. 
Sputum specimens were examined every month by 
microscopy and culture. three (two overnight and 
one spot) during the treatment phase and two (one 
overnight and one spot) during the follow-up phase. 
One positive sputum culture was tested each month 
for susceptibility to Isoniazid. Rifampicin and 
Ofloxacin. Sputum specimens were given 
identification laboratory numbers. and bacteriological 
investigations were carried out by technicians who 
were blind to the clinical status of the patient and the 
regimen. A chest radiograph was obtained during 
the first month and at the end of treatment. Patients 
who had clinical deterioration or had adverse 
reactions to anti-tuberculosis drugs were examined 
by a team of physicians and any decision to change 
or modify the regimen was made collectively. At the 
end of treatment, every case was reviewed by a panel 
consisting of two physicians. a bacteriologist and a 
statistician. Follow-up was designed to last 5 years; 
the results up to 24 months after treatment are 
presented here. 
Outcome: 
Primary outcome was recorded as follows: 
a) Bacteriological status at the end of treatment: The 
response to treatment was classified as "favourable" 
if all six sputum cultures in the last 2 months of 
treatment were negative: as "unfavourable" if one, 
or more, of the three cultures was positive in each 
of the last 2 months of treatment: and as "doubtful" 
if one or two cultures were positive in the last month 
of treatment but all the three cultures from the 
preceding month were negative. 
b) Bacteriological relapse: Among patients with a 
favourable or doubtful response at the end of 
treatment. bacteriological relapse was defined as a 
total of two or more positive cultures for 
Mycobacterium tuberculosis in any two consecutive 
months. Retreatment was started if one of the positive 
cultures yielded 20 colonies or more and if one of 
the smears was positive. 
Secondary outcome was recorded as  
follows: 
a) Sputum culture conversion at two months: The 
proportion of patients who became sputum culture 
negative at the end of two months of treatment. 
b) Adverse reactions to anti-tuberculosis drugs: The 
proportion of patients who developed adverse 
reactions attributable to the drugs in the treatment 
regimen 
Sample size : 
The sample size was calculated on the 
following basis. The efficacy of a 3-month regimen 
previously studied by the Tuberculosis Research 
Centre1 was 80%. and we anticipated an efficacy of 
95% for the current regimens. With a type I error of 
0.05. and a type II error of 0.20. the approximate 
sample size for each regimen was calculated to be 
115. Allowing for a 15% attrition in patients over 5- 
year follow-up period,the final sample size was 
calculated to be 115+17=132 or about 130 patients 
for each regimen. 
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Statistical analysis: 
Proportions of patients with primary and 
secondary outcomes (for patients with initially drug 
susceptible and drug resistant tuberculosis 
separately), in the four regimens. were compared 
using  X2test, and p value with 95% CI was 
calculated. 
Efficacy analysis was done for 416 patients 
who received a t  least 75% of  the prescribed 
chemotherapy. Intention-to-treat analysis was done 
for 469 (92%) of the 512 patients who fulfilled the 
eligibility criteria and were admitted to the study. 
The study protocol was cleared by the 
Scientific Advisory Coininittee and by the Institutional 
Ethical Committee of the Tuberculosis Research 
Centre. 
RESULTS 
The study commenced in November 1995 
and recruitment of cases was completed in November 
1998. A total of 529 patients were admitted to the 
study. Of these. 113 patients were excluded from 
analysis of efficacy ofthe regimens for the following 
reasons: 17 did not fulfill the eligibility criteria (11 
had only one or no positive sputum cultures initially, 
3 had received previous anti-tuberculosis treatment 
for more than 15 days. 2 were HIV sero-positive 
and I was less than 20 years of age); 51 received 
less than 75% of the prescribed treatment, 30 were 
lost to treatment for more than 1 month continuously, 
2 died of non-tuberculosis causes during treatment, 
1 died 11 days after starting treatment, 8 required a 
change in the regimen (5 because of adverse drug 
reactions and 3 due to pneumothorax), 2 refused 
treatment. and 2 received treatment for tuberculosis 
from a private practitioner after admission to the trial. 
We present data on the remaining 416 patients: 360 
with tuberculosis initially susceptible to Isoniazid, 
Rifampicin and Ofloxacin. and 56 with tuberculosis 
initially resistant to one or more drugs (47 to 
Isoniazid, 7 to Isoniazid and Rifampicin. 1 to 
Isoniazid, Rifampicin. and Ofloxacin, and 1 to 
Ofloxacin alone). 
Intention-to-treat analysis on 469 patients 
(404 with tuberculosis initially susceptible to all the 
drugs. and 65 with tuberculosis initially resistant to 
one or more drugs) is also given which includes 53 
of the 81 patients who either received less than 75% 
of the prescribed chemotherapy (48) or  missed 
treatment for more than 1 month continuously (5). 
The other 28 patients in these categories did not have 
data that permitted assessment of bacteriological 
response at the end of treatment (Figure 2). 
The baseline demographic and clinical 
characteristics of the 469 patients of intention-to - 
treat group were similar among the four treatment 
groups (Table 1). Male patients comprised 369 
(79%) of the total, and those aged 20 to 39 years, 
326 (70%) of the total. The mean body weight was 
42.1 kg (range 30.0 - 65.8 kg); 173 patients (37%)' 
weighed less than 40 kg, and only 11 (2%) weighed 
55 kg or more. Most patients had extensive, cavitary 
tuberculosis and 246 (52%) had 3+ or 3+ sputum 
smears. 
Table 1 : Characteristics of 469 smear positive 
pulmonary tuberculosis patients according 
Patients with drug-susceptible tuberculosis 
Response to treatment and Efficacy analysis: 
A total of 360 patients had tuberculosis that 
was initially susceptible to all the drugs used. Of 
these, 88 patients each were assigned to regimens 
O3,  O3-1, and O3-2. and 96 to regimen O2-2.  
Figure 3 presents the proportion of patients, month 
by month, who had negative cultures for all three 
monthly sputum specimens. Culture negativity by 
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Allocated to Intervention 
Received allocated regimens 
Did not receive allocated regimens 
Reasons : 
ineligible for entry to study 
Non-TB death/Early death 
Rx changed due to i)adverse 
reactions to regimen/(ii)pneumothorax 
Refused Rx/Took Rx elsewhere 
Missed >25% or 1 month Rx 
continuously 
Analysed for Efficacy of Regimens 
Analysed for Relapse (24 months after Rx) 
Excluded: 
Unfavourable at end of Rs 
Lost for follow-up 
Non-TB Death 
Had Rx for Hansen's Disease 
Intention-to-Treat analysis: 
Analysed for efficacy 
Missed >25% or 1 month Rx 
continuously 
Figure 2 : Flow diagram of patients from eligibility to analysis stages 
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the second month ranged from 92% to 98%. In all 
the four groups, 98% to 99% of patients had three 
negative cultures in the last month of treatment. 
Figure 3 : Month by month sputum culture conversion 
in 360 patients with tuberculosis initially 
susceptible to Isoniazid, Rifampicin and 
Ofloxacin (efficacy analysis) 
had an unfavourable bacteriological response, 7 who 
died of non-tuberculosis causes, 7 who were lost to 
follow-up and 1 who needed treatment for Hansen's 
disease), 341 patients were followed for 24 months 
after completing treatment. Of the 341 patients, 24 
(7%) had bacteriological relapse requiring 
retreatment: 7 (8%) of 83 in the O3 regimen (95% 
CI 3-17%), 3 (4%) of 81 in the 03-1 regimen (95% 
CI 1-10%), 2 (2%) of 86 in the O3-2 regimen (95% 
CI 1-8%), and 12 (13%) of 91 in the O2-2 regimen 
(95% CI 7-22%) (Table 2). In the relapsed patients, 
in 19 (79%), the relapse occurred in the first 6 
months of follow-up, and only one patient relapsed 
after 12 months. Eighteen of the 24 patients 
who relapsed received more than 90% of the 
prescribed chemotherapy and only 3 received less 
than 80%. 
Sputum culture drug susceptibility patterns 
were consistent with pre-treatment values in 22 of 
the 24 patients, but in the remaining 2 patients the 
Figure 4 : Response at end of treatment in 360 patients with tuberculosis initially susceptible to Isoniazid, 
Rifampicin and Ofloxacin (efficacy analysis) 
Four patients, one in each regimen, had an cultures at relapse were newly resistant to Isoniazid. 
unfavourable response at the end of treatment: one These two patients had received 96% and 99% of 
died in the second month of treatment (regimen O3-  the prescribed chemotherapy. The difference in the 
1) and 3 had persistent positive sputum cultures that relapse rates between patients who received regimen 
remained susceptible to all the drugs (Figure 4). Of O3-2 (2%) and those who received O2-2 (13%) 
the 15 patients who had doubtful response, all but was statistically significant (p=0.02). Also 
one (regimen O 3 )  subsequently had cultures that statistically significant was the difference in relapse 
became negative and remained so through the 24 rates between those who received 3 months of the 
months of follow-up. intensive Ofloxacin-containing phase (regimens O3, 
O3-  1, or O3-2, for which the mean relapse rate was 
Bacreriological relapse: 12/250, or 5%), and those who received only 2 
months of the intensive phase (regimen O2-2, for 
After the exclusion of 19 patients (4 who which the relapse rate was 12/91. or 13%) (p=0.02). 
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Regimen 
O3 
O3-1 
O3-2 
O2-2 
Isolated positive sputum cultures : 
Total Relapse Month of relapse post-treatment 
patients (n) % 1-6 7-12 13-19/21 
83 7 8 5 1 
81 3 4 3 0 
86 2 2 2 0 0 
91 12 13 9 3 0 
1 
0 
Forty-five patients had a single positive 
sputum culture during the follow-up period (9 in the 
O3 regimen, 12 in the O3-1 regimen, 16 in the 03-2 
regimen and 8 in the 02-2 regimen). In 12 patients 
these cultures occurred in the period up to 12 months, 
in 14 in the period 13-18'h month and in 19 patients 
in the period 19-24th month from the start of 
treatment. In all these patients, the sputum cultures 
in the months following the positive cultures were 
negative. One patient (regimen O3-1) produced one 
positive culture each in the 14th and 19th months. The 
subsequent cultures were negative. 
Patients with tuberculosis initially resistant only 
to Isoniazid 
Patients 
18 
8 
9 
12 
Response to treatment 
Favourable Doubtful Unfavourable Assessed Relapse Month of 
for relapse (n) relapse 
1-6 7-12 
15 2 1 15 3 
6 1 1 7 0 
9 0 0 9 2 1 1 
12 0 0 12 3 3 
The bacteriological response to treatment and 
the rates of relapse are shown in Table 3 for patients 
with tuberculosis initially resistant only to Isoniazid. 
Of 47 such patients. 2 (one each in regimens O3 and 
O3-1) had an unfavourable bacteriological response 
at the end of treatment. Both received only 79% of 
the prescribed chemotherapy but did not develop 
additional resistance during treatment. Two patients 
in the O3 regimen (both of whom subsequently 
relapsed) and one in the O3-1 regimen were classified 
as having a doubtful response to treatment. 
Bacteriological relapse : 
A total of43 ofthese patients were followed 
for 24 months after treatment. Relapse occurred in 
8 patients: 3 of 15 in the O3 regimen, 2 of 9 in the 
O3-2 regimen, and 3 of 12 in the O2-2 regimen. 
There were no relapses among the 7 patients in the 
O3-1 regimen. However, the numbers are small. All 
of the relapses occurred in the 12 months following 
the cessation of therapy - 5 in the first 6 months 
and 3 subsequently. All the 8 patients who relapsed 
had received between 84% and 100% of the 
prescribed chemotherapy. In 6 of the 8 patients, the 
drug susceptibility pattern of the sputum cultures at 
relapse was consistent with the pre-treatment pattern 
(Isoniazid resistant), but two had cultures that were 
susceptible to all the drugs. 
Isolated positive sputum cultures . 
Six patients had a single positive sputum 
culture during the follow-up period (2 in the O3 
regimen, 1 in the O3-2 regimen and 3 in the O2-2 
Reg. 
O3 
O3- 1 
O3-2 
O2-2 
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Table.2 : Outcome in 341 patients initially suceptible to Isoniazid, Rifampicin and Ofloxacin followed up 
for 24 months according to regimen (efficacy analysis) 
Table 3 : Response to treatment and relapse during follow-up in 47 patients initially resistant to isoniazid 
accoring to regimen (efficacy analysis) 
1 2 
regimen). In 4 patients these cultures occurred in 
the period up to 12 months, in 1 in the period 13- 18th 
month and in 1 patient in the period 19-24th month  
from the start of treatment. In all these patients, the 
sputum cultures in the months following the positive 
cultures were negative. 
Reg. Susceptible to all drugs 
Pts Fav Doubt Unfav 
n n n n (%) 
O3 97 90 6 1 (1) 
O3-1 103 96 5 2 (2) 
O3-2 104 98 3 3 (3) 
O2-2 100 96 2 2 (2) 
Patients with tuberculosis initially resistant to 
Isoniazid and Rifampicin 
Resistant to one/more drugs 
Pts Fav Doubt Unfav 
n n n n 
23 18 2 3 
l2 6 2 4 
14 12 0 2 
16 15 0 1 
Of 7 patients with initial resistance to 
isoniazid and Rifampicin, 5 had an unfavourable 
bacteriological response at the end of treatment (one 
each in regimens O3 and O3-2, and three in regimen 
O3-1). One patient (regimen O2-2) relapsed in the 
fifth month. Another patient, who had resistance to 
isoniazid, Rifampicin and Ofloxacin, responded well 
to treatment (regimen O2-2) and has continued to 
have negative sputum cultures through 24 months 
of follow-up. 
Pts 
n 
120 
115 
118 
116 
One patient with resistance to Ofloxacin 
alone (regimen O3) had a favourable response at the 
end of treatment, but died in the nineteenth month of 
follow-up for reasons unrelated to tuberculosis. 
Fav Doubt Unfav 
n n n(%) 
108 8 4 (3) 
102 7 6 (5) 
110 3 5 (4) 
111 2 3 (3) 
Intention-to-treat Analysis 
The Intention-to-treat analysis was done for 
469 patients (416 in efficacy analysis plus 53 patients 
who either received less than 75% of the prescribed 
treatment (48) or missed more than one month of 
treatment continuously (5). Of these 469 patients 
(404 with drug susceptible tuberculosis, 56 with initial 
resistance to isoniazid alone, 7 with initial resistance 
to Isoniazid and Rifampicin, 1 with initial resistance 
to Isoniazid, Rifampicin and Ofloxacin and 1 with 
initial resistance to Ofloxacin alone), 120. 115, 1 18 
and 116 were assigned to regimens O3,O3-1,O3-2 
and O2-2 respectively. Eighteen patients, consisting 
of4 (3%) in regimen O3,6 (5%) in regimen O3-1,5 
(4%) in regimen O3-2 and 3 (3%) in regimen O2-2, 
had an unfavourable bacteriological response at 
the end of treatment. Five of these 18 patients 
had initial resistance to Isoniazid and Rifampicin. 
(Table 4). 
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Table 4 : Response to treatment in 469 smear positive patients irrespective of compliance according to 
Adverse reactions to Drugs: 
Adverse reactions attributable to anti- 
tuberculosis drugs occurred in 31 % (regimen 02-2)- 
44% (regimen 03-2) of the 512 patients who were 
eligible for admission to the study (Table 5). This 
analysis, thus, includes patients who were excluded 
from the efficacy analysis. Modification of the 
treatment regimen was required in only 24 (5%) of 
all the patients. Arthralgia was reported by 25% to 
36% of patients in the four regimens, but only four 
patients required a change in the regimen: temporary 
withholding of Pyrazinamide in three patients, and a 
reduction of the dose in one. Patients who received 
2 months of pyrazinamide were less likely to develop 
arthralgia (25%) compared with patients who 
received 3 months of Pyrazinamide (36%), though 
this difference was not statistically significant 
(P=0.08). 
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regimen (intention-to-trat analysis) 
Fav - Favourable Doubt - Doubtful Unfav - Unfavourable 
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Sixteen patients developed jaundice; in 14 
the drugs were temporarily with held and then 
reintroduced. In the other two patients, the drugs 
were withheld because jaundice recurred after their 
reintroduction. Gastro-intestinal symptoms occurred 
in 6% to 9% of patients, requiring the withholding 
of Rifampicin in one patient. Cutaneous reactions 
occurred in 2% to 3%. but a modification of the 
regimen was necessary only for two patients. 
DISCUSSION 
Previous clinical trials of 3- or 4-month 
regimens for the treatment of smear positive 
pulmonary tuberculosis had not been successful. A 
3-month regimen of daily Streptomycin, Isoniazid. 
Rifampicin. and Pyrazinamide in the treatment of 
smear positive pulmonary tuberculosis in south India 
achieved high rates of culture conversion, but had 
relapse rates of 20% in the 21 months after treatment 
completion1. Eule et al, studying the same regimen, 
also reported a relapse rate of 20% among 61 
patients12. Likewise, a New Delhi study of 52 patients 
treated with Rifampicin, Isoniazid and Pyrazinamide 
for 8 weeks. followed by Rifampicin and Isoniazid 
for 4 weeks,reported a relapse rate of 23%13. 
Mehrotra reported a 6% relapse rate in 53 patients 
with a similar regimen but the definition of relapse 
also required the presence of radiological 
deterioration, in addition to positive sputum culture 
and so probably underestimated the actual relapse 
rate14. For 4-month regimens, the reported relapse 
rates are 13% in an East African and 10% 
in Singapore17,18. These studies suggest that 3- or 4- 
month regimens with traditional first-line anti- 
tuberculosis drugs may be inadequate for the 
treatment of smear positive pulmonary tuberculosis. 
Our study represents the first clinical trial 
of 3- to 5-month Ofloxacin-containing regimens for, 
the treatment of smear positive tuberculosis. The 
salient feature of this study is that the cure and the 
relapse rates in the 4-month O3-1 regimen and 5- 
month O3-2 regimen are comparable to the standard 
6-month regimens currently used19,20. The shorter 
duration of the studied regimens would hopefully 
improve patient adherence. Our 3-month regimen, 
while successful in achieving negative cultures in 
99% of patients with drug susceptible tuberculosis, 
had a relapse rate of 8% in 24 months. Nonetheless, 
this rate is much lower than the 20% relapse rate 
reported for a 3-month regimen in an earlier study1, 
with the added advantage that the regimen is fully 
oral. We have also shown that a supplement of 1 
month of Isoniazid and Rifampicin twice a week in 
the continuation phase could reduce the relapse rate 
to 4%. and a 2-month supplemental continuation 
phase still further to 2%. The relapse rate for the 4- 
month O2-2 regimen, however, was unacceptably 
high, at 13%, even though culture negativity at 2 
months was 97%. This strongly suggests that 2 
months of intensive phase is inadequate for 
sterilizing the bacterial load. Thus, for ultra- 
short regimens, at least 3 months of four 
bactericidal drugs in the intensive phase appears 
mandatory. 
Even though we were primarily interested 
in establishing the efficacy of the study regimens, 
an intention-to-treat analysis which included patients 
who had inadequate chemotherapy also gave very 
encouraging results with only 18 (4%) of469 patients 
having an unfavourable bacteriological response at 
the end of treatment. And, of these 18 patients, 5 
had initial multi-drug resistant tuberculosis. 
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study15,16 
TUBERCULOSIS RESEARCH CENTRE, CHENNAI 36 
The proportion of patients who become 
culture negative at 2 months is a measure of the 
bactericidal activity
c
of a regimen. In our study, 
culture negativity at 2 months ranged from 92% to 
98%. These high rates compare favourably with 
the earlier studies in which a regimen of Streptomycin, 
Isoniazid. Rifampicin, and Pyrazinamide daily resulted 
in culture negativity of 91% at 2 months1 and the 
same drugs given thrice weekly resulted in culture 
negativity of 89%21.These rates are also higher than 
the rates achieved with four-drug regimens using 
Ethambutol in place of Streptomycin (82%- 
88%22.23).The excellent rates of culture conversion 
in our study are important because culture 
conversion at 2 months has been shown to correlate 
well with lower relapse rate24. 
As in most clinical trials of short course 
chemotherapy, majority of the relapses occurred in 
the first 6 months after the end of treatment. This 
observation has been widely 
suggesting that a significant number of additional 
relapses beyond the 24-month period of follow-up 
would be unlikely. 
Possible adverse reactions to drugs 
occurred in 31% to 44% ofthe patients, but a majority 
of the reactions were mild and manageable with 
symptomatic treatment. Arthralgia attributable to 
Pyrazinamide was the most common adverse 
reaction, reported by 25% to 36% of the patients, 
but this complaint required a modification of the 
regimen in only four patients. Similarly, of the 16 
patients who developed jaundice, only 2 required a 
regimen change. The incidence of arthralgia and 
jaundice was comparable to that observed in our 
previous short-course studies using four drugs daily 
in the intensive phase1,11. We have also observed that 
the incidence of arthralgia and jaundice was 
considerably less in patients treated with four drugs 
thrice or twice weekly compared to those treated 
with the same drugs daily26. So, it is reasonable to 
presume that the adverse reactions in the current 
study could be reduced if the regimens could be given 
in an intermittent rhythm. 
It is for  note that  the rates of non- 
adherence to treatment and patient default 
remained high despite the still shorter regimens 
used in a carefully selected patient population: 
more than 20% of the patients in all the 
Indian Journal of Tuberculosis 
regimens did not complete the recommended 
number of doses. Thus, although 3- to 5-month 
regimens represent a significant advancement 
in the treatment of tuberculosis, even these 
regimens will require a stronger treatment 
discipline than currently exists in most countries 
where tuberculosis is endemic. 
While our protocol employed Ofloxacin, a 
fluoroquinolone derivative which is active against 
Mycobacterium tuberculosis, other fluoroquinolone 
derivatives may have similar or superior qualities. 
Levofloxacin, the L-isomer of Ofloxacin active 
isomer may be more effective than Ofloxacinz27 . 
Ofloxacin is, however, widely available and is less 
costly than levofloxacin. Newer fluoroquinolones 
may offer higher efficacy with similar low toxicity. 
The cost of a treatment regimen is always 
of great importance to a disease control programme. 
When we initiated this study in 1995, the cost of a 
single dose of 400 mg Ofloxacin was Indian Rs. 30/ 
- (US $ 0.66). Today, the same dose of Ofloxacin 
costs Rs. 6.50 as was the case with Rifampicin 
earlier. While the cost ofa 4-month regimen containing 
Ofloxacin for the initial 3 months would still be higher 
than that of the standard 6-month treatment for smear 
positive tuberculosis, the savings in terms of 
administrative costs would be considerable. With an 
intermittent regimen, the cost will be further reduced. 
The success with, 4- and 5-month 
regimens that contain Ofloxacin and other first- 
line anti-tuberculosis drugs, for a t  least three 
months in the intensive phase (high cure rates 
in newly diagnosed patients, low relapses, and 
good toleration) has made us embark  on a 
randomized clinical trial of fully intermittent 4- 
month regimens that include Ofloxacin. In the 
interim, a 4-month regimen of daily Ofloxacin, 
Isoniazid, Rifampicin, and Pyrazinamide for 3 
months, followed by 1 month of twice-weekly 
Isoniazid and Rifampicin, appears so far to be 
equally acceptable for the treatment of drug 
susceptible, smear positive pulmonary 
tuberculosis. 
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